Skip to main content
. 2020 Sep 10;2020:9057541. doi: 10.1155/2020/9057541

Table 2.

Characteristics of patients with HIV drug resistance mutations.

Code region of residence Age (years) Gender Transmission risk group∗∗ HIV genotype Drug resistance mutations (NRTI) Extent of ARVT (years NNRTI) The level of ARVT compliance∗∗∗ Plasma HIV-1 RNA (copies/ml)†† CD4+ cell count (cells/mm3)††
7 Krasn.Krai 40 M PWID A6 M184V K103N 5 High 598 376
9 Krasn. Krai 33 F Not available A6 A62V K65R V75I Y115F G190S 2 High 8310 343
40 Krasnoyarsk 36 F HTs A6 M184V K103N P225H 10 High 1170 598
61 Krasnoyarsk 58 F HTs A6 A62V K65R Y115F V179DY181C 10 Low 2270000 32
73 Norilsk 46 M HTs A6 M184V G190S K101Q 9 High 2703 265
74 Norilsk 43 M HTs A6 A62V D67E T69S_SA L210W T215F K101E V179F Y181C Y188L V106I K238R 6 High 3906 84
75 Norilsk 47 M HTs with PWID A6 A62V K65R M184V 10 High 13304 183
77 Norilsk 35 M PWID URF63/A M184V K101E E138G G190S 6 Average 27596 54
79 Norilsk 36 M PWID URF02/A M184 T215F K101E G190S V90I V106I 6 Average 379 135
80 Norilsk 45 M PWID A6 K103N 7 Average 1490 322
102 Krasnoyarsk 36 F HTs with PWID A6 Y181C 6 Average 7030 23
107 Krasnoyarsk 39 F HTs A6 K65R Y181C G190S K101Q 1 High 535000 239
109 Krasnoyarsk 37 M PWID A6 M184V T215F G190S K101Q 7 High 52500 293
110 Krasn. Krai 38 F HTs A6 A62V D67G E138K 3 Average 49500 473
131 Krasnoyarsk 45 M PWID URFA/B K65R, Y115D K103N Y181 V179I 1 Average 146000 123
149 Krasnoyarsk 39 F HTs A6 T215S 5 High 1640 296
150 Krasnoyarsk 38 M PWID A6 M184V K103N P225H 6 Average 4930 307
583 Norilsk 39 M PWID A6 D67N K70R A98G 10 High 1750 347
658 Norilsk 35 M PWID A6 A62V K70E M184V K101E E138A G190S 8 Average 342143 120
3 Krasnoyarsk 36 M HTs А6 L74I M184V K219E A98GY 181C G190S 6 Average 2600000 121
16.2 Krasn. Krai 33 F HTs А6 M41L L74I V75IM M184V T215S Q151M K103N E138K G190S 4 High 201000 148

Gender: M: male; F: female. ∗∗transmission risk group: PWID: people who inject drugs; HTs: people infected via heterosexual contacts. HIV-1 genotype: the result of HIV-1 genotyping obtained after analysis of the complex of data: phylogenetic analysis from RP-RT, IN, and env regions and additional recombination analysis in case of inconsistency of genotyping results. ∗∗∗The level of ARVT compliance was determined after individual interview with epidemiologist; ††plasma HIV-1 RNA and CD4+ cell count detected at the time of sampling of clinical blood samples.